Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 5/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.48 |
| ▸ | GPR3 | P46089 | 2/20 | 0.48 |
| ▸ | GABRP | O00591 | 2/20 | 0.47 |
| ▸ | GABRD | O14764 | 2/20 | 0.47 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.47 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.47 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.47 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.47 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.47 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.47 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.47 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.47 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.47 |
| ▸ | GABRE | P78334 | 2/20 | 0.47 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.47 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.47 |
| ▸ | GABRG3 | Q99928 | 2/20 | 0.47 |
| ▸ | GABRQ | Q9UN88 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3062795 | 0.81 | KIF11 (0.53) | KIF11ALDH1A1HSD17B10GPR3GABRP | |
| SCHEMBL6005278 | 0.81 | KIF11 (0.53) | KIF11ALDH1A1HSD17B10GPR3GABRP | |
| SCHEMBL21987846 | 0.81 | KIF11 (0.53) | KIF11ALDH1A1HSD17B10GPR3GABRP | |
| SCHEMBL3483748 | 0.81 | KIF11 (0.53) | KIF11ALDH1A1HSD17B10GPR3GABRP | |
| SCHEMBL9714208 | 0.81 | DYRK1A (0.54) | KIF11ALDH1A1HSD17B10GPR3GABRP | |
| SCHEMBL30355317 | 0.81 | DYRK1A (0.54) | KIF11ALDH1A1HSD17B10GPR3GABRP | |
| SCHEMBL9576581 | 0.78 | KIF11 (0.55) | KIF11ALDH1A1HSD17B10GPR3GABRP | |
| Biphenyl SCHEMBL27636641 | 0.77 | CYP19A1 (0.53) | KIF11ALDH1A1HSD17B10GPR3GABRP | |
| SCHEMBL11484516 | 0.75 | KIF11 (0.47) | KIF11ALDH1A1HSD17B10GPR3GABRP | |
| SCHEMBL27676787 | 0.74 | KIF11 (0.50) | KIF11ALDH1A1HSD17B10GPR3GABRP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 226 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107108555-A | Three ring atropisomer compounds | 百时美施贵宝公司 | 2017-08-29 | — | — | CN | claimed |
| CN-107074804-A | Carbazole derivates | 百时美施贵宝公司 | 2017-08-18 | — | — | CN | claimed |
| US-6908926-B1 | Substituted imidazoles, their preparation and use | NOVO NORDISK A/S (DK) | 2005-06-21 | — | — | US | claimed |
| US-11999720-B2 | Pyrazolylacylpyrazoline compounds and method for treating pain | THE TRUSTEES OF INDIANA UNIVERSITY (US) | 2024-06-04 | — | — | US | disclosed |
| US-20240173417-A1 | LUTEINIZING HORMONE-RELEASING HORMONE RECEPTOR (LHRH-R) CONJUGATES AND USES THEREOF | PURDUE RESEARCH FOUNDATION (US) | 2024-05-30 | — | — | US | disclosed |
| WO-2024102986-A2 | SARS-COV-2 MPRO INHIBITORS | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2024-05-16 | — | — | WO | disclosed |
| WO-2024102989-A1 | NON-PEPTIDIC SARS-COV-2 MAIN PROTEASE INHIBITORS | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2024-05-16 | — | — | WO | disclosed |
| US-11981684-B2 | Macrocyclic compounds and uses thereof | Turning Point Therapeutics, Inc. (US) | 2024-05-14 | — | — | US | disclosed |
| EP-3554526-B1 | LUTEINIZING HORMONE-RELEASING HORMONE RECEPTOR (LHRH-R) CONJUGATES AND USES THEREOF | PURDUE RESEARCH FOUNDATION (US) | 2024-05-08 | — | — | EP | disclosed |
| US-11939337-B2 | 1,5-disubstituted 1,2,3-triazoles are inhibitors of Rac/CDC42 GTPases | UNIVERSITY OF PUERTO RICO (US) | 2024-03-26 | — | — | US | disclosed |
| US-11925696-B2 | Carbonic anhydrase IX targeting agents and methods | PURDUE RESEARCH FOUNDATION (US) | 2024-03-12 | — | — | US | disclosed |
| EP-1348434-A1 | Use of pyridyl amides as inhibitors of angiogenesis | Fujisawa Deutschland GmbH (DE) | 2003-10-01 | — | — | EP | disclosed |
| US-6608098-B1 | Diabetes or obesity, 2-(4-(3-isopropyl-2,5-dioxo-2,3-dihydro-1H-pyrrolo(2,1-a) isoindol-9(5H)-yl)phenoxy)-N-propylacetamide | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2003-08-19 | — | — | US | disclosed |
| EP-1207161-A1 | NOVEL ISOINDOLE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2002-05-22 | — | — | EP | disclosed |
| EP-1123918-A1 | AROMATIC AMINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND AGENTS CONTAINING THE SAME | Takeda Chemical Industries, Ltd. (JP) | 2001-08-16 | — | — | EP | disclosed |
| EP-0663924-B1 | 17-BETA-CARBOXANILIDES OF 4-AZA-5-ALPHA-ANDROSTAN-3-ONES AS 5-ALPHA-REDUCTASE INHIBITORS | MERCK & CO INC (US) | 2001-02-14 | — | — | EP | disclosed |
| US-5693810-A | ENZYME INHIBITORS OF TESTOSTERONE-5ALPHA-REDUCTASE TO PREVENT OR LESSEN SYMPTOMS OF DIHYDROTESTOSTERONE-RELATED HYPERANDROGENIC CONDITIONS, E.G. PROSTATE PROBLEMS, SKIN DISORDERS | MERCK & CO., INC. (US) | 1997-12-02 | — | — | US | disclosed |
| EP-0663924-A4 | 17-g(b)-CARBOXANILIDES OF 4-AZA-5-g(a)-ANDROSTAN-3-ONES AS 5-g(a)-REDUCTASE INHIBITORS. | MERCK & CO INC (US) | 1995-10-04 | — | — | EP | disclosed |
| EP-0663924-A1 | 17$g(b)-CARBOXANILIDES OF 4-AZA-5$g(a)-ANDROSTAN-3-ONES AS 5$g(a)-REDUCTASE INHIBITORS | MERCK & CO. INC. (US) | 1995-07-26 | — | — | EP | disclosed |
| WO-1994007861-A1 | 17β-CARBOXANILIDES OF 4-AZA-5α-ANDROSTAN-3-ONES AS 5α-REDUCTASE INHIBITORS | MERCK & CO., INC. (US) | 1994-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11939337-B2 | 1,5-disubstituted 1,2,3-triazoles are inhibitors of Rac/CDC42 GTPases | CDC42, TNK2, RAC1 | KIF11 2655/4885ALDH1A1 3342/4885HSD17B10 3295/4885 |
| US-11925696-B2 | Carbonic anhydrase IX targeting agents and methods | CA9, CA13, CA12 | KIF11 3838/4885ALDH1A1 1908/4885HSD17B10 2737/4885 |
| US-20240173417-A1 | LUTEINIZING HORMONE-RELEASING HORMONE RECEPTOR (LHRH-R) CONJUGATES AND USES THEREOF | GNRHR, LHCGR, GHRHR | KIF11 1173/4885ALDH1A1 3003/4885HSD17B10 1209/4885 |
| US-11981684-B2 | Macrocyclic compounds and uses thereof | CSF3R, CSF1R, FLT3 | KIF11 1865/4885ALDH1A1 4474/4885HSD17B10 4579/4885 |
| US-11999720-B2 | Pyrazolylacylpyrazoline compounds and method for treating pain | ACHE, TRPV1, GRIK3 | KIF11 1211/4885ALDH1A1 814/4885HSD17B10 2160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.